Immunohistochemical expression of SMAD4, CK19, and CA19-9 in fine needle aspiration samples of pancreatic adenocarcinoma: Utility and potential role

CytoJournal

Volumn 4, Issue , 2007, Pages

  Zapata, Mauricio ^a   Cohen, Cynthia ^a   Siddiqui, Momin T ^a  

^a EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CYTOKERATIN 19; FORMALDEHYDE; PARAFFIN; SMAD4 PROTEIN;

ARTICLE; ASPIRATION BIOPSY; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER RESEARCH; COLON ADENOCARCINOMA; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; OVARY ADENOCARCINOMA; PANCREAS ADENOCARCINOMA; PROGNOSIS; PROTEIN EXPRESSION;

EID: 34547619392     PISSN: None     EISSN: 17426413     Source Type: Journal    
DOI: 10.1186/1742-6413-4-13     Document Type: Article

References (14)

1. Facts and Figures 2006. American Cancer Society, Atlanta: American Cancer Society 2006
2. Robbins & Cotran: Pathologic Basis of Disease. V Kumar A Abbas N Fausto, Elsevier Inc 7 2005
3. Cancer statistics, 1996. SL Parker T Tong S Bolden P Wingo, CA Cancer J Clin 1996 46 5 27 8548526
4. Cancer of the pancreas in Olmstead County, Minnesota, 1935-1975. N Maruchi D Brian J Ludwig LR Elveback LT Kurland, Mayo Clinical Procedures 1979 54 4 245 249
5. Cancers of the pancreas and biliary tract. Epidemiological considerations. JF Fraumeni, Cancer Res 1975 35 3437 46 1104153
6. Epidemiology of and risk factors for pancreatic cancer. EB Gold SB Goldin, Surgical Onocol Clin N Am 1998 7 1 67 91
7. Expression of novel markers of pancreatic ductal adenocarcinoma in pancreatic nonductal neoplasms: additional evidence of different genetic pathways. D Cao A Maitra JA Saavedra DS Klimstra NV Adsay RH Hruban, Mod Pathol 2005 18 6 752 761 10.1038/modpathol.3800363 15696124
8. Perioperative CA19-9 levels can predict stage and survival in patients with respectable pancreatic adenocarcinoma. CR Ferrone DM Finkelstein SP Thayer A Muzikansky C Fernandez-delCastillo AL Warshaw, J Clin Oncol 2006 20;24 18 2897 2902 10.1200/JCO.2005.05.3934
9. Genetic progression in the Pancreatic Ducts. R Hruban R Wilentz S Kern, Am J Pathol 2000 156 6 1821 1825 10854204
10. DPC4, a candidate tumor suppresser gene at human chromosome 18q21.1. SA Hahn M Schutte ATMS Hoque CA Moskaluk LT da Costa E Rozenblum CL Weinstein A Fischer CJ Yeo R Hruban SE Kern, Science 1996 271 5247 350 353 10.1126/science.271.5247.350 8553070
11. Allelotype of pancreatic adenocarcinoma using xenograft enrichment. SA Hahn AB Seymour ATMS Hoque M Schutte LT da Costa MS Redston C Caldas CL Weinstein A Fischer CJ Yeo R Hruban SE Kern, Cancer Res 1995 55 20 4670 4675 7553647
12. Role of Smad4 (DPC4) inactivation in human cancer. M Miyaki T Kuroki, Biochem Biophys Res Commun 2003 306 4 799 804 10.1016/S0006-291X(03)01066-0 12821112
13. Expresssion of G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcioma. YK Kang WH Kim JJ Jang, Hum Pathol 2002 33 9 877 883 10.1053/hupa.2002.127444 12378511
14. DPC4/Smad4 Expression and Outcome in Pancreatic Ductal Adenocarcinoma. A Biankin A Morey C Lee J Kench S Biankin H Hook D Head T Hugh R Sutherland S Henshall, J Clin Oncol 2002 20 23 4531 4542 10.1200/JCO.2002.12.063 12454109